Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tristel PLC (TSNLF)
Snailwell, GB
Operating both within the United Kingdom and globally, Tristel plc specializes in the development, production, and distribution of products designed for infection control. Its business is structured into three primary divisions: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and a third, unnamed 'Other' segment. Under its proprietary Tristel brand, the firm provides a comprehensive range of medical instrument disinfection solutions. These cater to a diverse array of applications, such as airway management, cardiology, ENT, endoscopy, gastrointestinal physiology, laboratory use, ophthalmology, phlebotomy, reproductive health/IVF, surface disinfection, ultrasound, urology, and women's health, alongside other related offerings. Established in 1993, Tristel plc maintains its headquarters in Snailwell, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +6.35% | -7.83% | +4.54% | +7.59% | +4.54% | +380.87% | +380.87% | +380.87% | +380.87% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Instruments & Supplies: +7.9%+10.8% ★ Q4'25: +22.4% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+0.0% Q4'25: +29.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+16.9% Q4'25: +19.9% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+18.7% ★ Q4'25: +19.6% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+26.3% ★ Q4'25: +61.4% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.4% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.51× ★ Q4'25: 0.22× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 5 Rev. Ana. 1 EPS Ana. |
Jun 2027 6 Rev. Ana. 1 EPS Ana. |
Jun 2028 2 Rev. Ana. 1 EPS Ana. |
Jun 2029 4 Rev. Ana. 1 EPS Ana. |
Jun 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
15.33M
est: 23.98M (-36.1%)
|
17.10M
est: 22.79M (-25.0%)
|
20.27M
est: 26.14M (-22.5%)
|
22.22M
est: 29.31M (-24.2%)
|
26.17M
est: 33.09M (-20.9%)
|
31.68M
est: 39.04M (-18.9%)
|
31.00M
est: 42.82M (-27.6%)
|
31.12M
est: 34.57M (-10.0%)
|
36.01M
est: 45.69M (-21.2%)
|
41.93M
est: 41.85M (+0.2%)
|
46.46M
est: 46.53M (-0.1%)
|
50.15M
49.97M – 50.46M
+7.8% YoY
|
55.16M
54.65M – 56.42M
+10.0% YoY
|
60.56M
60.16M – 61.46M
+9.8% YoY
|
70.56M
70.10M – 71.61M
+16.5% YoY
|
79.07M
78.55M – 80.25M
+12.1% YoY
|
| EBITDA |
3.41M
est: 5.00M (-32.0%)
|
3.66M
est: 4.76M (-23.0%)
|
5.21M
est: 5.46M (-4.5%)
|
5.54M
est: 6.12M (-9.4%)
|
6.22M
est: 6.91M (-10.0%)
|
9.30M
est: 8.15M (+14.1%)
|
6.20M
est: 8.94M (-30.6%)
|
4.53M
est: 7.21M (-37.3%)
|
7.90M
est: 9.54M (-17.2%)
|
10.01M
est: 8.79M (+13.8%)
|
11.48M
est: 9.77M (+17.4%)
|
10.54M
10.50M – 10.60M
+7.8% YoY
|
11.59M
11.48M – 11.85M
+10.0% YoY
|
12.72M
12.64M – 12.91M
+9.8% YoY
|
14.82M
14.73M – 15.04M
+16.5% YoY
|
16.61M
16.50M – 16.86M
+12.1% YoY
|
| EBIT |
2.54M
est: 3.60M (-29.4%)
|
2.59M
est: 3.42M (-24.2%)
|
3.90M
est: 3.92M (-0.5%)
|
4.01M
est: 4.40M (-8.9%)
|
4.75M
est: 4.96M (-4.4%)
|
6.81M
est: 5.86M (+16.2%)
|
4.83M
est: 6.42M (-24.8%)
|
1.82M
est: 5.18M (-65.0%)
|
5.35M
est: 6.85M (-22.0%)
|
7.30M
est: 6.06M (+20.6%)
|
8.68M
est: 6.73M (+28.9%)
|
7.26M
7.23M – 7.30M
+7.8% YoY
|
7.98M
7.91M – 8.16M
+10.0% YoY
|
8.76M
8.71M – 8.89M
+9.8% YoY
|
10.21M
10.14M – 10.36M
+16.5% YoY
|
11.44M
11.37M – 11.61M
+12.1% YoY
|
| Net Income |
2.22M
est: 2.06M (+7.5%)
|
2.10M
est: 2.82M (-25.4%)
|
3.42M
est: 3.55M (-3.6%)
|
3.27M
est: 3.96M (-17.3%)
|
4.03M
est: 4.97M (-18.8%)
|
5.10M
est: 5.85M (-12.9%)
|
3.66M
est: 4.75M (-23.1%)
|
-1.25M
est: 3.30M (-137.9%)
|
4.46M
est: 4.63M (-3.5%)
|
6.49M
est: 5.95M (+9.1%)
|
6.64M
est: 7.60M (-12.7%)
|
8.20M
8.13M – 8.36M
+7.8% YoY
|
9.62M
9.54M – 9.80M
+17.3% YoY
|
11.25M
11.15M – 11.46M
+16.9% YoY
|
13.76M
13.64M – 14.03M
+22.4% YoY
|
15.71M
15.58M – 16.02M
+14.2% YoY
|
| SGA |
7.24M
est: 12.81M (-43.5%)
|
8.24M
est: 12.17M (-32.3%)
|
10.34M
est: 13.96M (-25.9%)
|
10.97M
est: 15.65M (-29.9%)
|
13.58M
est: 17.67M (-23.1%)
|
15.45M
est: 20.85M (-25.9%)
|
16.38M
est: 22.86M (-28.4%)
|
17.92M
est: 18.45M (-2.9%)
|
20.22M
est: 24.40M (-17.1%)
|
23.12M
est: 23.12M (0.0%)
|
25.32M
est: 25.70M (-1.5%)
|
27.70M
27.60M – 27.87M
+7.8% YoY
|
30.47M
30.19M – 31.16M
+10.0% YoY
|
33.45M
33.23M – 33.95M
+9.8% YoY
|
38.97M
38.72M – 39.55M
+16.5% YoY
|
43.68M
43.39M – 44.33M
+12.1% YoY
|
| EPS |
0.05
est: 0.04 (+26.8%)
|
0.05
est: 0.06 (-14.6%)
|
0.08
est: 0.07 (+9.1%)
|
0.08
est: 0.08 (-7.5%)
|
0.09
est: 0.10 (-11.6%)
|
0.11
est: 0.12 (-9.8%)
|
0.08
est: 0.10 (-20.6%)
|
-0.03
est: 0.07 (-138.6%)
|
0.09
est: 0.10 (-2.0%)
|
0.14
est: 0.12 (+13.0%)
|
0.14
est: 0.16 (-11.6%)
|
0.17
0.17 – 0.17
+7.8% YoY
|
0.20
0.20 – 0.20
+17.3% YoY
|
0.23
0.23 – 0.24
+16.9% YoY
|
0.29
0.28 – 0.29
+22.4% YoY
|
0.33
0.32 – 0.33
+14.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Matthew G. Sassone | Chief Executive Officer & Director | 919.8K | male |
| Julija Shabanova | Executive Director | 490.9K | — |
| Aimee Scarbrow | Human Resources Director | — | — |
| Anna Katarzyna Wasyl | Chief Financial Officer & Director | — | female |
| Emily Davey | Global Marketing Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TSNLF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
